NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO) has received an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $16.71, slightly above its recent opening price of $15.94. The company surpassed quarterly earnings and revenue expectations, reporting $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Institutional investors hold a significant 98.5% of outstanding shares, while a director recently sold a portion of their holdings under a pre-arranged trading plan.
NeoGenomics | SCHEDULE 13G/A: Others
This article consists solely of the title "NeoGenomics | SCHEDULE 13G/A: Others" and the content "Document". It indicates the filing of a Schedule 13G/A for NeoGenomics, likely pertaining to an amendment by other reporting persons.
NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens
Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint account. First Light Asset Management independently holds a 7.99% stake, representing 10,260,186 shares.
California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO
The California State Teachers Retirement System significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% in the first quarter, now owning 194,103 shares valued at $1.44 million. This move is reflective of a broader positive sentiment from institutional investors, who collectively own 98.5% of the company. Analysts maintain a "Moderate Buy" rating with an average target price of $16.71, and NeoGenomics recently surpassed earnings and revenue estimates.
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan recently sold US$321k worth of company shares, representing an 80% reduction in his position. This significant insider selling, combined with no insider purchases over the last year, raises concerns about the company's valuation and signals caution for potential investors. Insiders currently own 2.1% of NeoGenomics shares, totaling approximately US$45 million.
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding
NeoGenomics' Senior VP & Chief Accounting Officer, Gregory Aunan, recently sold US$321k worth of shares, representing an 80% reduction in his holdings at an average price of US$16.07. This significant insider selling event, occurring slightly below the current share price of US$16.53, raises caution among investors despite insiders owning 2.1% of the company's shares. No insider purchases have been made over the last year, suggesting a cautious outlook for the company.
NeoGenomics announces planned departure of General Counsel Alicia Olivo
NeoGenomics, Inc. announced the planned departure of Alicia Olivo, Executive Vice President, General Counsel, and Business Development, effective September 21, 2026. Ms. Olivo will remain with the company until October 2, 2026, for a smooth transition and will receive separation payments as per her employment agreement. This announcement follows NeoGenomics reporting strong Q2 2026 earnings and revenue, surpassing Wall Street expectations, which led Needham to raise its price target for the company.
Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO
Renaissance Technologies LLC has acquired 254,172 shares of NeoGenomics, Inc. (NASDAQ:NEO) worth approximately $1.89 million, increasing institutional ownership of the company to 98.5%. This comes as NeoGenomics exceeded Q1 earnings expectations with $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Analysts maintain a "Moderate Buy" rating for NEO with an average price target of $16.71.
Technical Reactions to NEO Trends in Macro Strategies
This article provides a technical analysis of Neogenomics Inc. (NYSE: NEO) based on AI models, indicating strong sentiment across all time horizons and compelling upside potential. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis. The report suggests an overweight bias for NEO, citing the absence of resistance levels above the current price.
Form 8K NeoGenomics Inc For: 11 August By Investing.com
This article reports on NeoGenomics Inc.'s Form 8K filing for August 11th. The brief notice confirms the filing, and the article is primarily a placeholder for this regulatory update. No specific details about the content of the 8K filing are provided within this particular news item.
NeoGenomics announces planned departure of General Counsel Alicia Olivo
NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel, and Business Development, will depart from her role as General Counsel effective September 21, 2026, and will assist with the transition until October 2, 2026. This news follows the company's strong second-quarter 2026 earnings, which surpassed Wall Street expectations, leading Needham to raise its price target for NEO.
MFG Wealth Management Inc. Takes Position in NeoGenomics, Inc. $NEO
MFG Wealth Management Inc. has initiated a position in NeoGenomics, Inc. (NASDAQ:NEO) by purchasing 83,462 shares valued at approximately $1.22 million, representing about 0.06% of the company. Institutional investors and hedge funds collectively own 98.5% of NeoGenomics, which has received a "Moderate Buy" consensus rating from analysts with an average price target of $16.71. The medical research company recently exceeded quarterly expectations, reporting adjusted EPS of $0.05 and revenue of $201.66 million, an 11.2% increase year over year.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. has appointed Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of experience in commercial, product, and operations roles at data and technology companies, with significant expertise in AI and data insights in cancer care. Her appointment is expected to help NeoGenomics expand its portfolio and enhance its impact on cancer patients through innovative diagnostic solutions.
Neogenomics stock hits 52-week high at 16.46 USD
NeoGenomics Inc. (NEO) stock has reached a 52-week high of $16.46, driven by strong investor confidence and recent positive financial results. Despite being considered overvalued by InvestingPro analysis, the company's stock has delivered a 170% return over the past year, with analysts predicting profitability and upward earnings revisions. NeoGenomics also reported strong Q2 2026 earnings, exceeding expectations and leading to raised full-year guidance.
NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?
NeoGenomics (NEO) reported a return to quarterly profitability in Q2 2026 with revenue of US$201.66 million and a net income of US$2.24 million, a significant improvement from a net loss the previous year. Management also narrowed its expected full-year 2026 net loss and slightly raised its revenue outlook, signaling increased confidence in the business. This positive financial performance and updated guidance may reshape the investment narrative for NeoGenomics, particularly concerning its long-term path to sustained profitability and its fair value projections.
NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co.
Sei Investments Co. significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 320.7% during the first quarter, now holding 466,199 shares valued at $3.46 million. This move is mirrored by other institutional investors, collectively owning 98.5% of the company's stock, despite a recent insider share sale. Analysts maintain a "Moderate Buy" rating for NeoGenomics, with an average price target of $16.71, and the company recently surpassed quarterly earnings expectations.
Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO
Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 9.2% in the first quarter, purchasing an additional 225,588 shares, bringing its total holdings to 2.67 million shares valued at approximately $19.8 million. This acquisition reflects a broader institutional interest in NeoGenomics, with several other large investors also adjusting their positions. The medical research company recently reported strong quarterly earnings, exceeding analyst expectations with an EPS of $0.05 and an 11.2% year-over-year revenue increase, while analysts maintain a "Moderate Buy" consensus rating for the stock.
How NeoGenomics’ Q2 Profit Return And Higher 2026 Outlook At NeoGenomics (NEO) Has Changed Its Investment Story
NeoGenomics (NEO) reported a return to profitability in Q2 2026 with US$2.24 million net income and raised its full-year 2026 revenue outlook to US$802 million–US$806 million, indicating improving operational performance. This positive shift strengthens the company's investment narrative, emphasizing its role as a specialized oncology testing player. However, valuation risks remain due to a relatively new management team and potential overvaluation of shares.
NeoGenomics, Inc. Revenue Breakdown – BX:NG9
NeoGenomics, Inc. (BX:NG9) generated 576.61 million CHF in revenue last year. The "Client Direct Billing" segment was the top performer, contributing 411.32 million CHF, a decrease from the previous year. The United States was the primary regional contributor, accounting for all of the company's revenue.
NeoGenomics Laboratories Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, NeoGenomics Laboratories, a Biotech and Healthcare Services company founded in 2002 and headquartered in Fort Myers, Florida, has approximately 2,124 total employees worldwide. This represents a 2.5% growth from 2023 but a 2.2% year-over-year decline in 2026. The company is actively hiring, with 121 active job postings in 2026, a 20.0% increase from 2025.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeoGenomics, Inc. (NEO) recently hit a new 52-week high, with its stock up 4.5% in the past month and 34.7% since the start of the year. This outperformance is attributed to strong earnings surprises, with expected EPS growth of 50% for the current fiscal year and 95.83% for the next. While the stock trades at a premium valuation, its Zacks Rank of #2 (Buy) and strong Growth and Momentum Style Scores suggest potential for further gains.
NEO5107997 Bond Profile — Key Metrics
This article provides key metrics for the NEO5107997 bond issued by NeoGenomics, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of NeoGenomics, Inc., a clinical laboratory company specializing in cancer genetics diagnostic testing.
NEO Stock Price and Chart — NASDAQ:NEO
This article provides a comprehensive overview of NeoGenomics, Inc. (NASDAQ: NEO), including its stock price performance, key financial metrics, recent earnings report, and analyst ratings. It highlights the company's Q2 2026 revenue growth and increased full-year guidance. The article also includes various trading ideas and technical analyses from the community, alongside information on ETFs holding NEO stock.
BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update
BlackRock, Inc. has filed an amended beneficial ownership report revealing a 15.6% stake in NeoGenomics, Inc., totaling 20,358,331 shares. Of these, BlackRock holds sole voting power over 19,688,877 shares and sole dispositive power over all 20,358,331 shares. The filing also notes that the iShares Core S&P Small-Cap ETF has an interest exceeding five percent of NeoGenomics' outstanding common stock.
First Trust entities disclose 10.1M-share NeoGenomics (NEO) position in 13G
First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, disclosing beneficial ownership of 10,113,261 shares of NeoGenomics (NEo), which represents 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation hold shared voting and dispositive power over these shares, primarily through unit investment trusts. The reporting entities collectively disclaim beneficial ownership of these shares despite the filing.
NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed?
NeoGenomics (NEO) recently finalized a civil settlement with the U.S. Department of Justice for US$9.8 million plus interest, resolving an investigation into legacy agreements. The settlement, which involved no admission of liability and was covered by previous reserves, removes a compliance overhang. While this clears one risk, the company's investment narrative now focuses more on the adoption of new oncology tests, like the FDA-approved PTEN IHC diagnostic, and its ability to achieve profitable growth despite current losses and a high valuation.
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 47% Upside
Analyst estimates have led to an increased average 12-month price target for NeoGenomics, Inc. (NEO) stock, rising from $16.78 to $19.72, with a range of $16 to $35 per share. This updated target suggests a potential upside of approximately 47% from its closing price on July 28. The consensus rating from 12 covering analysts remains a "Buy," with 8 Buy ratings and 4 Holds.
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 47% Upside
NeoGenomics, Inc. (NEO) has seen its average 12-month price target raised from $16.78 to $19.72 by 9 analysts, implying a 47% potential upside based on the July 28 closing price. The consensus rating for the stock remains a "Buy" with 8 buys and 4 holds among 12 covering analysts. Investors can find more detailed price target data and analyst recommendations on TradingView's Forecasts tab and News Flow.
NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve
NeoGenomics (NEO) stock rallied by 14% after reporting a swing from a Q1 loss to a modest Q2 profit, driven by improved margins and increased average price per test. While clinical revenue and NGS growth are strong, concerns remain regarding the decline in pharma services revenue and the company's balance sheet challenges. Investors are focusing on whether the operational improvements can justify its premium valuation despite ongoing headwinds.
Needham raises Neogenomics stock price target on strong Q2 results
Needham has increased its price target for Neogenomics Inc. (NASDAQ:NEO) to $19.00 from $15.00, maintaining a Buy rating, following strong second-quarter 2026 results. The company surpassed revenue and EBITDA consensus estimates, leading management to raise full-year guidance and indicating a potential return to profitability this year. NeoGenomics also launched new assays and expects to be free cash flow neutral to positive in 2026.
Neogenomics stock hits 52-week high at 15.61 USD
NeoGenomics Inc. (NEO) stock reached a 52-week high of $15.61 USD, representing a 162.75% increase over the past year. Despite trading above its Fair Value, analysts are optimistic about the company turning profitable this year. This surge follows strong second-quarter 2026 earnings, where NeoGenomics surpassed Wall Street expectations, leading Needham to raise its price target to $19.00 with a Buy rating.
NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics, Inc. announced its second-quarter 2026 results, showing an 11% year-over-year increase in total revenue to $202 million, with robust clinical services revenue growth of 14% driven by a 26% increase in NGS revenue. The company reported a GAAP net income of $2 million and an adjusted EBITDA of $14 million, marking a 36% increase. Following these strong results, NeoGenomics has raised its full-year 2026 revenue and adjusted EBITDA guidance.
Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO
Gamco Investors INC. ET AL significantly increased its stake in NeoGenomics, Inc. by 525% in the first quarter, now holding 100,000 shares valued at $742,000. This move comes as NeoGenomics reported better-than-expected Q2 earnings and raised its fiscal 2026 revenue guidance, despite ongoing concerns about its negative net margin and return on equity. Institutional investors collectively own 98.5% of the company, and analysts currently rate the stock as a "Hold" with a consensus target price of $14.57.
Needham raises Neogenomics stock price target on strong Q2 results
Needham has increased its price target for Neogenomics Inc. (NASDAQ: NEO) to $19.00 from $15.00, maintaining a Buy rating after the company reported strong Q2 2026 results. NeoGenomics surpassed revenue and EBITDA estimates and raised its full-year guidance, driven by significant organic revenue growth and new product launches. Analysts predict the company will achieve profitability this year.
NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...
NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance to $56 million to $58 million, reflecting confidence in continued growth. Despite these positive indicators, the nonclinical pharma segment experienced a notable decline, posing a challenge that the company aims to address by 2027.
NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28
This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their financial performance for the second quarter of 2026.
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
NeoGenomics (NASDAQ:NEO) reported strong Q2 CY2026 results, exceeding Wall Street's expectations for revenue and adjusted EPS. The oncology diagnostics company's revenue grew 11.2% year-on-year to $201.7 million, with an adjusted EPS of $0.05. NeoGenomics also slightly raised its full-year revenue and adjusted EPS guidance, indicating a positive outlook for the company.
NeoGenomics (NASDAQ:NEO) Posts Earnings Results, Beats Expectations By $0.02 EPS
NeoGenomics (NASDAQ:NEO) reported quarterly earnings that surpassed analyst expectations, with an EPS of $0.05 against an estimated $0.03, and revenue of $201.66 million, exceeding the $196.93 million estimate. Despite the positive earnings surprise, the company posted a negative net margin and return on equity. Shares saw an increase in trading, and while analysts maintain a "Hold" consensus, some have raised price targets, reflecting cautious optimism, with institutional investors holding a significant stake in the company.
Earnings call transcript: NeoGenomics tops Q2 2026 estimates and lifts outlook
NeoGenomics Inc. reported strong second-quarter 2026 earnings, surpassing Wall Street expectations for both profit and sales, driven by robust clinical and next-generation sequencing (NGS) business growth. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, despite continued weakness in its non-clinical pharma segment. Management highlighted strategies for continued durable and profitable growth through high-value testing and operational efficiencies, while also addressing analyst concerns about NGS growth sustainability and the role of the pharma business.
NeoGenomics Releases Q2 2026 Financial Results
NeoGenomics, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.05, significantly beating analyst estimates, and revenue of $201.7M, surpassing consensus. The company saw an 11.2% increase in revenue year-over-year, primarily driven by its clinical services segment. Management provided full-year adjusted EPS guidance of $0.17 to $0.20, reflecting analyst confidence in its market position within genomic cancer diagnostics.
NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed?
NeoGenomics recently finalized a civil settlement with the U.S. Department of Justice for nearly $10 million, resolving a compliance overhang after an internal investigation into past agreements. Despite a 7.7% stock drop, the settlement amount is manageable given prior reserves, and the company is focusing on expanding its oncology test menu, including an FDA-approved PTEN IHC companion diagnostic for prostate cancer. The key for investors remains the successful adoption of new tests and managing high fixed costs as the company approaches its Q2 2026 earnings.
NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals
NeoGenomics Laboratories has agreed to pay nearly $10 million to settle allegations that it violated the False Claims Act. The settlement comes after NeoGenomics self-disclosed providing below-market-value consulting services to healthcare providers who referred patients for laboratory testing and paying variable referral-based compensation to independent consultants. The U.S. acknowledged NeoGenomics' significant cooperation, including ending problematic consulting agreements and terminating responsible employees.
First Light Asset Management LLC Has $72.20 Million Position in NeoGenomics, Inc. $NEO
First Light Asset Management LLC slightly reduced its stake in NeoGenomics, Inc. by 3% in Q1, but it remains its third-largest position, valued at $72.2 million. NeoGenomics, a cancer-focused genetic testing provider, reported strong Q1 revenue growth of 11.3% year-over-year but remains unprofitable. Analyst sentiment is mixed, with a "Hold" consensus rating and an average price target of $14.57.
NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350
This article provides an overview of Neogenomics Inc (NEO) stock performance and basic financial information. It shows the current stock price, market cap, and a note that a stock score is unavailable due to insufficient data. The article also mentions various sections like Financials, Discussions, Analysis, and Company details.
NEO Income Statement
This article from TradingKey provides an overview of Neogenomics Inc.'s (NEOUSD) income statement. It explains how to interpret quarterly and annual financial data, defines key metrics like YOY, and highlights important figures such as revenue, gross profit, operating profit, and EPS for stock analysis. The page is intended for investors seeking insights into the company's financial performance and operational efficiency.
NEOGENOMICS INC : BENCHMARK RAISES TARGET PRICE TO $16 FROM $11
Benchmark has increased its target price for NEOGENOMICS INC (NEO.O) shares to $16 from the previous $11. This adjustment reflects a positive outlook on the company's financial prospects. The information was released by Reuters on July 24, 2026.
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Raises Target Price to $16
Benchmark Co. has reiterated its Buy rating on NeoGenomics (NEO.US) and increased its price target to $16. This adjustment reflects the firm's continued confidence in the company's prospects.
NeoGenomics Inc. (NEO) Q3 2025 Earnings Report - Results, Call & Slides
NeoGenomics Inc. (NEO) has released its Q3 2025 earnings report. The company beat consensus estimates with actual EPS of $0.53 against an expected $0.37, and actual revenue of $3.29 billion surpassing the expected $3.22 billion. NeoGenomics also announced a Q3 2025 earnings call held on October 28, 2025, and estimated its next earnings date for July 28, 2026.
NEO Maintained by Benchmark -- Price Target Raised to $16.00
Benchmark maintained a Buy rating on NeoGenomics (NEO) and raised its price target to $16.00, up from the previous $11.00. GuruFocus indicates that NEO is currently undervalued by 14.7% with a GF Value™ of $16.69 and holds a solid GF Score™ of 72/100, though insider activity shows some selling pressure. This suggests a compelling investment case, tempered by the need for caution regarding insider selling and profitability metrics.
NeoGenomics Inc. (NG9) Q2 2025 Earnings Report - Results, Call & Slides
NeoGenomics Inc. (NG9) released its Q2 2025 earnings report, indicating a beat on EPS with €0.03 against a consensus of €0.02, but missed revenue expectations at €159.26M versus an anticipated €160.42M. The company experienced a 10.23% year-over-year revenue growth. The earnings call was scheduled for Tuesday, July 29, 2025, before the market open, and the next earnings report is estimated for July 28, 2026.
